Chagas' disease: An update on immune mechanisms and therapeutic strategies

Journal of Cellular and Molecular Medicine

Volumn 14, Issue 6 B, 2010, Pages 1373-1384

  Boscardin, Silvia Beatriz ^a   Torrecilhas, Ana Claudia Troccoli ^a,b   Manarin, Romina ^c   Revelli, Silvia ^c   Rey, Elena Gonzalez ^d   Tonelli, Renata Rosito ^e   Silber, Ariel Mariano ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b Mackenzie Presbeterian University   (Brazil)

^c FACULTAD DE CIENCIAS MÉDICAS   (Argentina)

^d INSTITUTO DE PARASITOLOGÍA Y BIOMEDICINA LÓPEZ NEYRA   (Spain)

^e FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Chagas' disease; Chemotherapy; Immunity; Immunoparasitology; Trypanosoma cruzi

Indexed keywords

CHAGAS DISEASE; HUMAN; IMMUNOLOGY; PARASITOLOGY; REVIEW; TRYPANOSOMA CRUZI;

CHAGAS DISEASE; HUMANS; TRYPANOSOMA CRUZI;

KINETOPLASTIDA; PROTOZOA; TRYPANOSOMA CRUZI; TRYPANOSOMATIDAE;

EID: 77955123701     PISSN: 15821838     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1582-4934.2010.01007.x     Document Type: Review

References (126)

1. Alves MJ, Colli W. Trypanosoma cruzi: adhesion to the host cell and intracellular survival. IUBMB Life. 2007, 59:274-9.
2. Punukollu G, Gowda RM, Khan IA. Clinical aspects of the Chagas' heart disease. Int J Cardiol. 2007, 115:279-83.
3. Moncayo A, Ortiz Yanine MI. An update on Chagas disease (human American trypanosomiasis). Ann Trop Med Parasitol. 2006, 100:663-77.
4. Gattuso JM, Kamm MA. The management of constipation in adults. Aliment Pharmacol Ther. 1993, 7:487-500.
5. Walker M, Zunt JR. Parasitic central nervous system infections in immunocompromised hosts. Clin Infect Dis. 2005, 40:1005-15.
6. Duschak VG, Couto AS. An insight on targets and patented drugs for chemotherapy of Chagas disease. Recent Pat Antiinfect Drug Discov. 2007, 2:19-51.
7. Maya JD, Cassels BK, Iturriaga-Vasquez P. Mode of action of natural and synthetic drugs against Trypanosoma cruzi and their interaction with the mammalian host. Comp Biochem Physiol. 2007, 146:601-20.
8. Cazzulo JJ. Proteinases of Trypanosoma cruzi: patential targets for the chemotherapy of Changas desease. Curr Top Med Chem. 2002, 2:1261-71.
9. Barr SC, Warner KL, Kornreic BG. A cysteine protease inhibitor protects dogs from cardiac damage during infection by Trypanosoma cruzi. Antimicrob Agents Chemother. 2005, 49:5160-1.
10. Engel JC, Doyle PS, Hsieh I. Cysteine protease inhibitors cure an experimental Trypanosoma cruzi infection. J Exp Med. 1998, 188:725-34.
11. Urbina JA. Chemotherapy of Chagas' disease: the how and the why. J Mol Med. 1999, 77:332-8.
12. Urbina JA. Ergosterol biosynthesis and drug development for Chagas disease. Mem Inst Oswaldo Cruz. 2009, 104:311-8.
13. Docampo R, Moreno SN. Bisphosphonates as chemotherapeutic agents against trypanosomatid and apicomplexan parasites. Curr Drug Targets Infect Disord. 2001, 1:51-61.
14. Esteva MI, Kettler K, Maidana C. Benzophenone-based farnesyltransferase inhibitors with high activity against Trypanosoma cruzi. J Med Chem. 2005, 48:7186-91.
15. Rivarola HW, Paglini-Oliva PA. Trypanosoma cruzi trypanothione reductase inhibitors: phenothiazines and related compounds modify experimental Chagas' disease evolution. Curr Drug Targets Cardiovasc Haematol Disord. 2002, 2:43-52.
16. Paveto C, Guida MC, Esteva MI. Anti-Trypanosoma cruzi activity of green tea (Camellia sinensis) catechins. Antimicrob Agents Chemother. 2004, 48:69-74.
17. Chamond N, Goytia M, Coatnoan N. Trypanosoma cruzi proline racemases are involved in parasite differentiation and infectivity. Mol Microbiol. 2005, 58:46-60.
18. Magdaleno A, Ahn IY, Paes LS. Actions of a proline analogue, L-thiazolidine-4-carboxylic acid (T4C), on Trypanosoma cruzi. PLoS ONE. 2009, 4:e4534.
19. Almeida DR, Carvalho AC, Branco JN. Chagas' disease reactivation after heart transplantation: efficacy of allopurinol treatment. J Heart Lung Transplant. 1996, 15:988-92.
20. Bodley AL, Shapiro TA. Molecular and cytotoxic effects of camptothecin, a topoisomerase I inhibitor, on trypanosomes and Leishmania. Proc Natl Acad Sci USA. 1995, 92:3726-30.
21. Gonzales-Perdomo M, de Castro SL, Meirelles MN. Trypanosoma cruzi proliferation and differentiation are blocked by topoisomerase II inhibitors. Antimicrob Agents Chemother. 1990, 34:1707-14.
22. Rowland EC, Moore-Lai D, Seed JR. Inhibition of in vitro intracellular growth of Trypanosoma cruzi by dicationic compounds. J Parasitol. 2003, 89:1078-80.
23. Stephens CE, Brun R, Salem MM. The activity of diguanidino and 'reversed' diamidino 2,5-diarylfurans versus Trypanosoma cruzi and Leishmania donovani. Bioorg Med Chem Lett. 2003, 13:2065-9.
24. Stolić I, Miškovic K, Magdaleno A. Effect of 3,4-ethylenedioxy-extension of thiophene core on the DNA/RNA binding properties and biological activity of bisbenzimidazole amidines. Bioorg Med Chem. 2009, 17:2544-54.
25. Abrahamsohn IA, Coffman RL. Trypanosoma cruzi: IL-10, TNF, IFN-gamma, and IL-12 regulate innate and acquired immunity to infection. Exp Parasitol. 1996, 84:231-44.
26. Rottenberg ME, Bakhiet M, Olsson T. Differential susceptibilities of mice genomically deleted of CD4 and CD8 to infections with Trypanosoma cruzi or Trypanosoma brucei. Infect Immun. 1993, 61:5129-33.
27. Tarleton RL, Koller BH, Latour A. Susceptibility of beta 2-microglobulin-deficient mice to Trypanosoma cruzi infection. Nature. 1992, 356:338-40.
28. Campos MA, Gazzinelli RT. Trypanosoma cruzi and its components as exogenous mediators of inflammation recognized through Toll-like receptors. Mediators Inflamm. 2004, 13:139-43.
29. Takeda K, Akira S. Toll-like receptors. Curr Protoc Immunol. 2007, Chapter 14:Unit 14 2
30. Campos MA, Closel M, Valente EP. Impaired production of proinflammatory cytokines and host resistance to acute infection with Trypanosoma cruzi in mice lacking functional myeloid differentiation factor 88. J Immunol. 2004, 172:1711-8.
31. Koga R, Hamano S, Kuwata H. TLR-dependent induction of IFN-beta mediates host defense against Trypanosoma cruzi. J Immunol. 2006, 177:7059-66.
32. Shoda LK, Kegerreis KA, Suarez CE. DNA from protozoan parasites Babesia bovis, Trypanosoma cruzi, and T. brucei is mitogenic for B lymphocytes and stimulates macrophage expression of interleukin-12, tumor necrosis factor alpha, and nitric oxide. Infect Immun. 2001, 69:2162-71.
33. Bafica A, Santiago HC, Goldszmid R. Cutting edge: TLR9 and TLR2 signaling together account for MyD88-dependent control of parasitemia in Trypanosoma cruzi infection. J Immunol. 2006, 177:3515-9.
34. Rottenberg ME, Rodriguez DA, Orn A. Control of Trypanosoma cruzi infection in mice deprived of T-cell help. Scand J Immunol. 1992, 36:261-8.
35. Kumar S, Tarleton RL. The relative contribution of antibody production and CD8+ T cell function to immune control of Trypanosoma cruzi. Parasite Immunol. 1998, 20:207-16.
36. Tzelepis F, de Alencar BC, Penido ML. Distinct kinetics of effector CD8+ cytotoxic T cells after infection with Trypanosoma cruzi in naive or vaccinated mice. Infect Immun. 2006, 74:2477-81.
37. Tarleton RL, Grusby MJ, Zhang L. Increased susceptibility of Stat4-deficient and enhanced resistance in Stat6-deficient mice to infection with Trypanosoma cruzi. J Immunol. 2000, 165:1520-5.
38. Frank FM, Petray PB, Cazorla SI. Use of a purified Trypanosoma cruzi antigen and CpG oligodeoxynucleotides for immunoprotection against a lethal challenge with trypomastigotes. Vaccine. 2003, 22:77-86.
39. Frank FM, Cazorla SI, Sartori MJ. Elicitation of specific, Th1-biased immune response precludes skeletal muscle damage in cruzipain-vaccinated mice. Exp Mol Pathol. 2008, 84:64-70.
40. Muller U, Sobek V, Balkow S. Concerted action of perforin and granzymes is critical for the elimination of Trypanosoma cruzi from mouse tissues, but prevention of early host death is in addition dependent on the FasL/Fas pathway. Eur J Immunol. 2003, 33:70-8.
41. Martin DL, Weatherly DB, Laucella SA. CD8+ T-Cell responses to Trypanosoma cruzi are highly focused on strain-variant trans-sialidase epitopes. PLoS Pathog. 2006, 2:e77.
42. Tzelepis F, de Alencar BC, Penido ML. Infection with Trypanosoma cruzi restricts the repertoire of parasite-specific CD8+ T cells leading to immunodominance. J Immunol. 2008, 180:1737-48.
43. Bixby LM, Tarleton RL. Stable CD8+ T cell memory during persistent Trypanosoma cruzi infection. J Immunol. 2008, 181:2644-50.
44. Araujo AF, de Alencar BC, Vasconcelos JR. CD8+-T-cell-dependent control of Trypanosoma cruzi infection in a highly susceptible mouse strain after immunization with recombinant proteins based on amastigote surface protein 2. Infect Immun. 2005, 73:6017-25.
45. Boscardin SB, Kinoshita SS, Fujimura AE. Immunization with cDNA expressed by amastigotes of Trypanosoma cruzi elicits protective immune response against experimental infection. Infect Immun. 2003, 71:2744-57.
46. Vasconcelos JR, Hiyane MI, Marinho CR. Protective immunity against Trypanosoma cruzi infection in a highly susceptible mouse strain after vaccination with genes encoding the amastigote surface protein-2 and trans-sialidase. Hum Gene Ther. 2004, 15:878-86.
47. Garg N, Tarleton RL. Genetic immunization elicits antigen-specific protective immune responses and decreases disease severity in Trypanosoma cruzi infection. Infect Immun. 2002, 70:5547-55.
48. Santos Lima EC, Minoprio P. Chagas' disease is attenuated in mice lacking gamma delta T cells. Infect Immun. 1996, 64:215-21.
49. Nomizo A, Cardillo F, Postol E. V gamma 1 gammadelta T cells regulate type-1/type-2 immune responses and participate in the resistance to infection and development of heart inflammation in Trypanosoma cruzi-infected BALB/c mice. Microbes Infect. 2006, 8:880-8.
50. Lieke T, Graefe SE, Klauenberg U. NK cells contribute to the control of Trypanosoma cruzi infection by killing free parasites by perforin-independent mechanisms. Infect Immun. 2004, 72:6817-25.
51. Rottenberg M, Cardoni RL, Andersson R. Role of T helper/inducer cells as well as natural killer cells in resistance to Trypanosoma cruzi infection. Scand J Immunol. 1988, 28:573-82.
52. Duthie MS, Wleklinski-Lee M, Smith S. During Trypanosoma cruzi infection CD1d-restricted NK T cells limit parasitemia and augment the antibody response to a glycophosphoinositol-modified surface protein. Infect Immun. 2002, 70:36-48.
53. Kotner J, Tarleton R. Endogenous CD4+ CD25+ regulatory T cells have a limited role in the control of Trypanosoma cruzi infection in mice. Infect Immun. 2007, 75:861-9.
54. Sales PA, Golgher D, Oliveira RV. The regulatory CD4+CD25+ T cells have a limited role on pathogenesis of infection with Trypanosoma cruzi. Microbes Infect. 2008, 10:680-8.
55. Holscher C, Kohler G, Muller U. Defective nitric oxide effector functions lead to extreme susceptibility of Trypanosoma cruzi-infected mice deficient in gamma interferon receptor or inducible nitric oxide synthase. Infect Immun. 1998, 66:1208-15.
56. Marinho CR, Nunez-Apaza LN, Martins-Santos R. IFN-gamma, but not nitric oxide or specific IgG, is essential for the in vivo control of low-virulence Sylvio X10/4 Trypanosoma cruzi parasites. Scand J Immunol. 2007, 66:297-308.
57. Michailowsky V, Silva NM, Rocha CD. Pivotal role of interleukin-12 and interferon-gamma axis in controlling tissue parasitism and inflammation in the heart and central nervous system during Trypanosoma cruzi infection. Am J Pathol. 2001, 159:1723-33.
58. Rodrigues MM, Ribeirao M, Boscardin SB. CD4 Th1 but not Th2 clones efficiently activate macrophages to eliminate Trypanosoma cruzi through a nitric oxide dependent mechanism. Immunol Lett. 2000, 73:43-50.
59. Machado FS, Souto JT, Rossi MA. Nitric oxide synthase-2 modulates chemokine production by Trypanosoma cruzi-infected cardiac myocytes. Microbes Infect. 2008, 10:1558-66.
60. Talvani A, Ribeiro CS, Aliberti JC. Kinetics of cytokine gene expression in experimental chagasic cardiomyopathy: tissue parasitism and endogenous IFN-gamma as important determinants of chemokine mRNA expression during infection with Trypanosoma cruzi. Microbes Infect. 2000, 2:851-66.
61. Hardison JL, Wrightsman RA, Carpenter PM. The chemokines CXCL9 and CXCL10 promote a protective immune response but do not contribute to cardiac inflammation following infection with Trypanosoma cruzi. Infect Immun. 2006, 74:125-34.
62. Machado FS, Koyama NS, Carregaro V. CCR5 plays a critical role in the development of myocarditis and host protection in mice infected with Trypanosoma cruzi. J Infect Dis. 2005, 191:627-36.
63. Hardison JL, Kuziel WA, Manning JE. Chemokine CC receptor 2 is important for acute control of cardiac parasitism but does not contribute to cardiac inflammation after infection with Trypanosoma cruzi. J Infect Dis. 2006, 193:1584-8.
64. Galvao Da Silva AP, Jacysyn JF, De Almeida Abrahamsohn I. Resistant mice lacking interleukin-12 become susceptible to Trypanosoma cruzi infection but fail to mount a T helper type 2 response. Immunology. 2003, 108:230-7.
65. Castanos-Velez E, Maerlan S, Osorio LM. Trypanosoma cruzi infection in tumor necrosis factor receptor p55-deficient mice. Infect Immun. 1998, 66:2960-8.
66. Kroll-Palhares K, Silverio JC, Silva AA. TNF/TNFR1 signaling up-regulates CCR5 expression by CD8+ T lymphocytes and promotes heart tissue damage during Trypanosoma cruzi infection: beneficial effects of TNF-alpha blockade. Mem Inst Oswaldo Cruz. 2008, 103:375-85.
67. Hunter CA, Ellis-Neyes LA, Slifer T. IL-10 is required to prevent immune hyperactivity during infection with Trypanosoma cruzi. J Immunol. 1997, 158:3311-6.
68. Abrahamsohn IA, da Silva AP, Coffman RL. Effects of interleukin-4 deprivation and treatment on resistance to Trypanosoma cruzi. Infect Immun. 2000, 68:1975-9.
69. Kierszenbaum F. Protection of congenitally athymic mice against Trypanosoma cruzi infection by passive antibody transfer. J Parasitol. 1980, 66:673-5.
70. Krettli AU, Brener Z. Protective effects of specific antibodies in Trypanosoma cruzi infections. J Immunol. 1976, 116:755-60.
71. Krettli AU, Weisz-Carrington P, Nussenzweig RS. Membrane-bound antibodies to bloodstream Trypanosoma cruzi in mice: strain differences in susceptibility to complement-mediated lysis. Clin Exp Immunol. 1979, 37:416-23.
72. Lages-Silva E, Ramirez LE, Krettli AU. Effect of protective and non-protective antibodies in the phagocytosis rate of Trypanosoma cruzi blood forms by mouse peritoneal macrophages. Parasite Immunol. 1987, 9:21-30.
73. Lima-Martins MV, Sanchez GA, Krettli AU. Antibody-dependent cell cytotoxicity against Trypanosoma cruzi is only mediated by protective antibodies. Parasite Immunol. 1985, 7:367-76.
74. Okabe K, Kipnis TL, Calich VL. Cell-mediated cytotoxicity to Trypanosoma cruzi. I. Antibody-dependent cell mediated cytotoxicity to trypomastigote bloodstream forms. Clin Immunol Immunopathol. 1980, 16:344-53.
75. Cardillo F, Postol E, Nihei J. B cells modulate T cells so as to favour T helper type 1 and CD8+ T-cell responses in the acute phase of Trypanosoma cruzi infection. Immunology. 2007, 122:584-95.
76. Hoft DF, Eickhoff CS, Giddings OK. Trans-sialidase recombinant protein mixed with CpG motif-containing oligodeoxynucleotide induces protective mucosal and systemic Trypanosoma cruzi immunity involving CD8+ CTL and B cell-mediated cross-priming. J Immunol. 2007, 179:6889-900.
77. Albareda MC, Laucella SA, Alvarez MG. Trypanosoma cruzi modulates the profile of memory CD8+ T cells in chronic Chagas' disease patients. Int Immunol. 2006, 18:465-71.
78. Dutra WO, Martins-Filho OA, Cancado JR. Chagasic patients lack CD28 expression on many of their circulating T lymphocytes. Scand J Immunol. 1996, 43:88-93.
79. Stolf NA, Higushi L, Bocchi E. Heart transplantation in patients with Chagas' disease cardiomyopathy. J Heart Transplant. 1987, 6:307-12.
80. Vaidian AK, Weiss LM, Tanowitz HB. Chagas' disease and AIDS. Kinetoplastid Biol Dis. 2004, 3:2.
81. Bustamante JM, Novarese M, Rivarola HW. Reinfections and Trypanosoma cruzi strains can determine the prognosis of the chronic chagasic cardiopathy in mice. Parasitol Res. 2007, 100:1407-10.
82. Hyland KV, Leon JS, Daniels MD. Modulation of autoimmunity by treatment of an infectious disease. Infect Immun. 2007, 75:3641-50.
83. Tzelepis F, Persechini PM, Rodrigues MM. Modulation of CD4+ T cell-dependent specific cytotoxic CD8+ T cells differentiation and proliferation by the timing of increase in the pathogen load. PLoS ONE. 2007, 2:e393.
84. Fuenmayor C, Higuchi ML, Carrasco H. Acute Chagas' disease: immunohistochemical characteristics of T cell infiltrate and its relationship with T. cruzi parasitic antigens. Acta Cardiol. 2005, 60:33-7.
85. Higuchi MD, Ries MM, Aiello VD. Association of an increase in CD8+ T cells with the presence of Trypanosoma cruzi antigens in chronic, human, chagasic myocarditis. Am J Trop Med Hyg. 1997, 56:485-9.
86. Reis DD, Jones EM, Tostes S. Characterization of inflammatory infiltrates in chronic chagasic myocardial lesions: presence of tumor necrosis factor-alpha+ cells and dominance of granzyme A+, CD8+ lymphocytes. Am J Trop Med Hyg. 1993, 48:637-44.
87. Abel LC, Rizzo LV, Ianni B. Chronic Chagas' disease cardiomyopathy patients display an increased IFN-gamma response to Trypanosoma cruzi infection. J Autoimmun. 2001, 17:99-107.
88. Ribeirao M, Pereira-Chioccola VL, Renia L. Chagasic patients develop a type 1 immune response to Trypanosoma cruzi trans-sialidase. Parasite Immunol. 2000, 22:49-53.
89. Gomes JA, Bahia-Oliveira LM, Rocha MO. Evidence that development of severe cardiomyopathy in human Chagas' disease is due to a Th1-specific immune response. Infect Immun. 2003, 71:1185-93.
90. Souza PE, Rocha MO, Rocha-Vieira E. Monocytes from patients with indeterminate and cardiac forms of Chagas' disease display distinct phenotypic and functional characteristics associated with morbidity. Infect Immun. 2004, 72:5283-91.
91. Laucella SA, Postan M, Martin D. Frequency of interferon- gamma -producing T cells specific for Trypanosoma cruzi inversely correlates with disease severity in chronic human Chagas disease. J Infect Dis. 2004, 189:909-18.
92. Fonseca SG, Reis MM, Coelho V. Locally produced survival cytokines IL-15 and IL-7 may be associated to the predominance of CD8+ T cells at heart lesions of human chronic Chagas disease cardiomyopathy. Scand J Immunol. 2007, 66:362-71.
93. Cunha-Neto E, Dzau VJ, Allen PD. Cardiac gene expression profiling provides evidence for cytokinopathy as a molecular mechanism in Chagas' disease cardiomyopathy. Am J Pathol. 2005, 167:305-13.
94. Dutra WO, Gollob KJ, Pinto-Dias JC. Cytokine mRNA profile of peripheral blood mononuclear cells isolated from individuals with Trypanosoma cruzi chronic infection. Scand J Immunol. 1997, 45:74-80.
95. Talvani A, Rocha MO, Barcelos LS. Elevated concentrations of CCL2 and tumor necrosis factor-alpha in chagasic cardiomyopathy. Clin Infect Dis. 2004, 38:943-50.
96. Alvarez MG, Postan M, Weatherly DB. HLA Class I-T Cell Epitopes from trans-Sialidase Proteins Reveal Functionally Distinct Subsets of CD8 T Cells in Chronic Chagas Disease. PLoS Negl Trop Dis. 2008, 2:e288.
97. Diez H, Lopez MC, Del Carmen Thomas M. Evaluation of IFN-gamma production by CD8 T lymphocytes in response to the K1 peptide from KMP-11 protein in patients infected with Trypanosoma cruzi. Parasite Immunol. 2006, 28:101-5.
98. Fonseca SG, Moins-Teisserenc H, Clave E. Identification of multiple HLA-A*0201-restricted cruzipain and FL-160 CD8+ epitopes recognized by T cells from chronically Trypanosoma cruzi-infected patients. Microbes Infect. 2005, 7:688-97.
99. Marin-Neto JA, Cunha-Neto E, Maciel BC. Pathogenesis of chronic Chagas heart disease. Circulation. 2007, 115:1109-23.
100. Bonney KM, Engman DM. Chagas heart disease pathogenesis: one mechanism or many. Curr Mol Med. 2008, 8:510-8.
101. Benvenuti LA, Roggerio A, Freitas HF. Chronic American trypanosomiasis: parasite persistence in endomyocardial biopsies is associated with high-grade myocarditis. Ann Trop Med Parasitol. 2008, 102:481-7.
102. Bilate AM, Teixeira PC, Ribeiro SP. Distinct outcomes of Trypanosoma cruzi infection in hamsters are related to myocardial parasitism, cytokine/chemokine gene expression, and protein expression profile. J Infect Dis. 2008, 198:614-23.
103. Sathler-Avelar R, Vitelli-Avelar DM, Massara RL. Benznidazole treatment during early-indeterminate Chagas' disease shifted the cytokine expression by innate and adaptive immunity cells toward a type 1-modulated immune profile. Scand J Immunol. 2006, 64:554-63.
104. Rodriques Coura J, de Castro SL. A critical review on Chagas disease chemotherapy. Mem Inst Oswaldo Cruz. 2002, 97:3-24.
105. Lages-Silva E, Filardi LS, Brener Z. Effect of the host specific treatment in the phagocytosis of Trypanosoma cruzi blood forms by mouse peritoneal macrophages. Mem Inst Oswaldo Cruz. 1990, 85:401-5.
106. Murta SM, Ropert C, Alves RO. In-vivo treatment with benznidazole enhances phagocytosis, parasite destruction and cytokine release by macrophages during infection with a drug-susceptible but not with a derived drug-resistant Trypansoma cruzi population. Parasite Immunol. 1999, 21:535-44.
107. Romanha AJ, Alves RO, Murta SM. Experimental chemotherapy against Trypanosoma cruzi infection: essential role of endogenous interferon-gamma in mediating parasitologic cure. J Infect Dis. 2002, 186:823-8.
108. Bustamante JM, Bixby LM, Tarleton RL. Drug-induced cure drives conversion to a stable and protective CD8+ T central memory response in chronic Chagas disease. Nat Med. 2008, 14:542-50.
109. Olivieri BP, Cotta-De-Almeida V, Araujo-Jorge T. Benznidazole treatment following acute Trypanosoma cruzi infection triggers CD8+ T-cell expansion and promotes resistance to reinfection. Antimicrob Agents Chemother. 2002, 46:3790-6.
110. Caldas IS, Talvani A, Caldas S. Benznidazole therapy during acute phase of Chagas disease reduces parasite load but does not prevent chronic cardiac lesions. Parasitol Res. 2008, 103:413-21.
111. Bahia-Oliveira LM, Gomes JA, Cancado JR. Immunological and clinical evaluation of chagasic patients subjected to chemotherapy during the acute phase of Trypanosoma cruzi infection 14-30 years ago. J Infect Dis. 2000, 182:634-8.
112. Michailowsky V, Murta SM, Carvalho-Oliveira L. Interleukin-12 enhances in vivo parasiticidal effect of benznidazole during acute experimental infection with a naturally drug-resistant strain of Trypanosoma cruzi. Antimicrob Agents Chemother. 1998, 42:2549-56.
113. Vitelli-Avelar DM, Sathler-Avelar R, Teixeira-Carvalho A. Strategy to assess the overall cytokine profile of circulating leukocytes and its association with distinct clinical forms of human Chagas disease. Scand J Immunol. 2008, 68:516-25.
114. Sathler-Avelar R, Vitelli-Avelar DM, Massara RL. Etiological treatment during early chronic indeterminate Chagas disease incites an activated status on innate and adaptive immunity associated with a type 1-modulated cytokine pattern. Microbes Infect. 2008, 10:103-13.
115. Revelli S, Le Page C, Piaggio E. Benznidazole, a drug employed in the treatment of Chagas' disease, down-regulates the synthesis of nitrite and cytokines by murine stimulated macrophages. Clin Exp Immunol. 1999, 118:271-7.
116. Piaggio E, Sanceau J, Revelli S. Trypanocidal drug benznidazole impairs lipopolysaccharide induction of macrophage nitric oxide synthase gene transcription through inhibition of NF-kb activation. J Immunol. 2001, 167:3422-6.
117. Piaggio E, Roggero E, Pitashny M. Treatment with benznidazole and its immunomodulating effects on Trypanosoma cruzi-infected rats. Parasitol Res. 2001, 87:539-47.
118. Pascutti MF, Pitashny M, Nocito AL. Benznidazole, a drug used in Chagas' disease, ameliorates LPS-induced inflammatory response in mice. Life Sci. 2004, 76:685-97.
119. Manarin R, Bottasso E, Bottasso O. Beneficial effects of benznidazole during an infectious-based situation of systemic inflammatory response: cecal ligation and puncture. Am J Trop Med Hyg. 2008, 79:793-6.
120. Cabeza Meckert P, Chambo JG, Laguens RP. Differences in resistance to reinfection with low and high inocula of Trypanosoma cruzi in chagasic mice treated with nifurtimox and relation to immune response. Antimicrob Agents Chemother. 1988, 32:241-5.
121. Lelchuk R, Cardoni RL, Levis S. Nifurtimox-induced alterations in the cell-mediated immune response to PPD tin guinea-pigs. Clin Exp Immunol. 1977, 30:469-73.
122. Lelchuk R, Cardoni RL, Fuks AS. Cell-mediated immunity in Chagas' disease: alterations induced by treatment with a trypanocidal drug (nifurtimox). Clin Exp Immunol. 1977, 30:434-8.
123. Sanchez-Burgos G, Mezquita-Vega RG, Escobedo-Ortegon J. Comparative evaluation of therapeutic DNA vaccines against Trypanosoma cruzi in mice. FEMS Immunol Med Microbiol. 2007, 50:333-41.
124. Tarleton RL. Chagas disease: a role for autoimmunity? Trends Parasitol. 2003, 19:447-51.
125. da Silva AL. Chagas disease surgery. Mem Inst Oswaldo Cruz. 1999, 94:343-7.
126. Soares MB, Garcia S, Campos de Carvalho AC. Cellular therapy in Chagas' disease: potential applications in patients with chronic cardiomyopathy. Regen Med. 2007, 2:257-64.